{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:09:48Z","timestamp":1778724588864,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universite Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pharma.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:42:51Z","timestamp":1775180571000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["R\u00f4le cl\u00e9 du pharmacien en lien avec le m\u00e9decin g\u00e9n\u00e9raliste et le n\u00e9phrologue dans la prise en charge de la MRC"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne M.","family":"Laville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.03.004_bib0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.pharma.2026.03.004_bib0180","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2026.03.004_bib0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2026.03.004_bib0190","first-page":"e184852","article-title":"Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open","volume":"1","author":"Tonelli","year":"2018"},{"key":"10.1016\/j.pharma.2026.03.004_bib0195","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0200","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2\u00a0diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.26502\/fccm.92920229","article-title":"Point-of-care capillary blood creatinine: a prospective study in cardiology and nephrology outpatients","volume":"5","author":"Vilaine","year":"2021","journal-title":"Cardiol Cardiovasc Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nephro.2021.08.009","article-title":"[Prevalence of chronic kidney disease in Antananarivo, Madagascar]","volume":"18","author":"Ranivoharisoa","year":"2022","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pharma.2026.03.004_bib0220","unstructured":"D\u00e9cision du 22\u00a0avril 2025\u00a0de l\u2019Union nationale des caisses d\u2019assurance maladie relative \u00e0 la liste des actes et prestations pris en charge par l\u2019assurance maladie."},{"key":"10.1016\/j.pharma.2026.03.004_bib0225","unstructured":"Acad\u00e9mie Nationale de Pharmacie. Maladie r\u00e9nale chronique\u00a0: D\u00e9pistage et pr\u00e9vention des risques de la iatrog\u00e9nie m\u00e9dicamenteuse. 2020."},{"key":"10.1016\/j.pharma.2026.03.004_bib0230","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nephro.2015.10.001","article-title":"N\u00e9phropathie aux acides aristolochiques et n\u00e9phropathie end\u00e9mique des Balkans","author":"Nortier","year":"2015","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pharma.2026.03.004_bib0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.therap.2020.02.019","article-title":"Self-medication practices and their characteristics among French university students","volume":"75","author":"Gras","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.pharma.2026.03.004_bib0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nephro.2022.07.305","article-title":"\u00c9valuation de l\u2019autom\u00e9dication chez les insuffisants r\u00e9naux chroniques","volume":"18","author":"Mekaouche","year":"2022","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pharma.2026.03.004_bib0245","article-title":"R\u00f4les et implication du pharmacien d\u2019officine dans le parcours de soin du patient atteint de maladie r\u00e9nale chronique","author":"Pauwels","year":"2025","journal-title":"Sciences pharmaceutiques"},{"issue":"8","key":"10.1016\/j.pharma.2026.03.004_bib0250","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/ndt\/gft388","article-title":"The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study","volume":"29","author":"Stengel","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2026.03.004_bib0255","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2026.03.004_bib0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ndt.2023.1","article-title":"Groupe N\u00e9phrologie verte de la SFNDT\u00a0: premi\u00e8res r\u00e9flexions","volume":"19","author":"Chazot","year":"2023","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pharma.2026.03.004_bib0265","series-title":"Indicateurs pour l\u2019am\u00e9lioration de la qualit\u00e9 et de la s\u00e9curit\u00e9 des soins. Prise en charge des patients h\u00e9modialys\u00e9s chroniques. R\u00e9sultats nationaux de la campagne 2015 - Donn\u00e9es 2014\u00a0et 2015","year":"2015"},{"key":"10.1016\/j.pharma.2026.03.004_bib0270","series-title":"Bonnes pratiques de pharmacie hospitali\u00e8re","year":"2001"},{"key":"10.1016\/j.pharma.2026.03.004_bib0275","first-page":"c337","article-title":"The randomized controlled trial","volume":"113","author":"Stel","year":"2009","journal-title":"NEC"},{"key":"10.1016\/j.pharma.2026.03.004_bib0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfz199","article-title":"The nephrology crystal ball: the medium-term future","volume":"35","author":"Zoccali","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2026.03.004_bib0285","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ndt\/gfz023","article-title":"Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials","volume":"34","author":"Zoccali","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2026.03.004_bib0290","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073\u00a0as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"JASN"},{"key":"10.1016\/j.pharma.2026.03.004_bib0295","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0300","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0305","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2\u00a0diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.03.004_bib0310","series-title":"Dictionary of pharmacoepidemiology","author":"Begaud","year":"2000"},{"issue":"7","key":"10.1016\/j.pharma.2026.03.004_bib0315","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bcp.14713","article-title":"Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study","volume":"87","author":"Liabeuf","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2026.03.004_bib0320","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.01030120","article-title":"Adverse drug reactions in patients with CKD","volume":"15","author":"Laville","year":"2020","journal-title":"CJASN"},{"key":"10.1016\/j.pharma.2026.03.004_bib0325","doi-asserted-by":"crossref","first-page":"sfae357","DOI":"10.1093\/ckj\/sfae357","article-title":"Quantifying the potential contribution of drugs to the occurrence of acute kidney injury in patients with chronic kidney disease","volume":"18","author":"Laville","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.pharma.2026.03.004_bib0330","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/cts.13084","article-title":"Consequences of oral antithrombotic use in patients with chronic kidney disease","volume":"14","author":"Laville","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharma.2026.03.004_bib0335","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ekir.2021.06.004","article-title":"Prescription of direct oral anticoagulants to patients with moderate-to-advanced CKD: too little or just right?","volume":"6","author":"Liabeuf","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharma.2026.03.004_bib0340","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin Drug Investig"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:43:04Z","timestamp":1778722984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"alternative-id":["S0003450926000428"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R\u00f4le cl\u00e9 du pharmacien en lien avec le m\u00e9decin g\u00e9n\u00e9raliste et le n\u00e9phrologue dans la prise en charge de la MRC","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}